Is This the Next Home-Run Biotech Stock?
Alzheimer's disease is incredibly tough to treat, and 99% of Alzheimer's disease drugs to enter clinical trials have failed. But Axovant Sciences (NYSE:AXON) thinks it's designed a trial that can pan out, and given that its management includes been-there and done-that leaders, it may not be smart to bet against it.